Interestingly, IL-6 pathway inhibitors are currently tested in combination with chemotherapy in patients with BCA (NCT03135171), pancreatic cancer (NCT04258150, NCT02767557), or liver cancer (NCT04338685), who displayed potent anti-cancer activity with a low incidence of IL-6 drug toxicity [6]. This evidence concerns the gene IL6 and liver cancer.